

Our Pipeline

Beating pathogens acquired by mucosal infection by inducing antibodies that mediate the killing of infected cells.

To realize our vision, we plan to gain commercial approval for the Δ gD-2 vaccine for the prevention of HSV type 1 and type 2. In addition, the potential for therapeutic application of the vaccine is under investigation.

X-VAX Development Projects

